[Skip to Navigation]
Observation
January 2015

Rapid Involution of Choroidal Metastasis Secondary to Renal Cell Carcinoma With Oral Sunitinib

Author Affiliations
  • 1Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, Iowa City
JAMA Ophthalmol. 2015;133(1):109-110. doi:10.1001/jamaophthalmol.2014.3931

Oral sunitinib malate (Sutent) is a tyrosine kinase inhibitor that prevents binding of vascular endothelial growth factor and platelet-derived growth factor to their native receptors.1 It has been approved by the US Food and Drug Administration for the treatment of renal cell carcinoma (RCC) and imatinib mesylate–resistant gastrointestinal stromal tumor. Choroidal metastasis from RCC is rare, composing only 3% of all choroidal metastases.2 Herein, we report the first case, to our knowledge, of rapid involution of choroidal metastasis secondary to RCC using sunitinib.

×